Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 27, 2022

SELL
$0.38 - $0.81 $123,265 - $262,751
-324,384 Reduced 50.46%
318,451 $168,000
Q2 2022

Jul 27, 2022

BUY
$0.5 - $2.66 $59,846 - $318,383
119,693 Added 22.88%
642,835 $325,000
Q1 2022

Apr 25, 2022

BUY
$1.87 - $4.77 $200,030 - $510,237
106,968 Added 25.7%
523,142 $1.2 Million
Q4 2021

Feb 01, 2022

BUY
$3.5 - $8.42 $521,878 - $1.26 Million
149,108 Added 55.83%
416,174 $1.98 Million
Q3 2021

Oct 19, 2021

SELL
$6.03 - $7.95 $90,462 - $119,265
-15,002 Reduced 5.32%
267,066 $2.12 Million
Q2 2021

Jul 15, 2021

BUY
$6.32 - $8.38 $848,636 - $1.13 Million
134,278 Added 90.86%
282,068 $1.96 Million
Q1 2021

Apr 26, 2021

SELL
$6.76 - $8.57 $88,522 - $112,224
-13,095 Reduced 8.14%
147,790 $1.17 Million
Q4 2020

Feb 01, 2021

BUY
$7.02 - $9.83 $277,577 - $388,688
39,541 Added 32.59%
160,885 $1.27 Million
Q3 2020

Oct 07, 2020

SELL
$6.51 - $9.33 $1.38 Million - $1.97 Million
-211,387 Reduced 63.53%
121,344 $860,000
Q2 2020

Jul 21, 2020

BUY
$4.01 - $11.04 $1.33 Million - $3.67 Million
332,731 New
332,731 $3.08 Million
Q4 2019

Jan 17, 2020

SELL
$7.23 - $8.55 $92,565 - $109,465
-12,803 Closed
0 $0
Q3 2019

Oct 16, 2019

SELL
$6.42 - $9.0 $1.25 Million - $1.75 Million
-194,991 Reduced 93.84%
12,803 $98,000
Q2 2019

Aug 12, 2019

BUY
$6.1 - $8.78 $693,978 - $998,874
113,767 Added 120.99%
207,794 $1.42 Million
Q1 2019

Apr 26, 2019

BUY
$7.6 - $9.4 $714,605 - $883,853
94,027 New
94,027 $757,000

Others Institutions Holding AGLE

# of Institutions
1
Shares Held
241K
Call Options Held
0
Put Options Held
0

About Aeglea BioTherapeutics, Inc.


  • Ticker AGLE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,172,500
  • Market Cap $1.69B
  • Description
  • Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...
More about AGLE
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.